Brexafemme (ibrexafungerp) — Highmark
recurrent vulvovaginal candidiasis (RVVC)
Preferred products
- fluconazole
Initial criteria
- Diagnosis of RVVC (ICD10: B37.32)
- Member has experienced three or more episodes of VVC in less than one year
- Member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole
Approval duration
6 months